• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

关于代表不同临床亚型的乳腺癌细胞系在连续传代过程中激素和生长因子受体谱改变的数据。

Data on alteration of hormone and growth factor receptor profiles over progressive passages of breast cancer cell lines representing different clinical subtypes.

作者信息

Nair Madhumathy G, Desai Krisha, Prabhu Jyothi S, Hari P S, Remacle Jose, Sridhar T S

机构信息

Division of Molecular Medicine, St. John׳s Research Institute, Bangalore, India.

出版信息

Data Brief. 2016 Jul 6;8:944-7. doi: 10.1016/j.dib.2016.07.001. eCollection 2016 Sep.

DOI:10.1016/j.dib.2016.07.001
PMID:27508248
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4961495/
Abstract

Human breast cancers are a highly heterogeneous group of tumours consisting of several molecular subtypes with a variable profile of hormone, growth factor receptors and cytokeratins [1]. Here, the data shows immunofluorescence profiling of four different cell lines belonging to distinct clinical subtypes of breast cancer. Post revival, the cell lines were passaged in culture and immunophenotyping was done for ER, HER-2, AR and EGFR. Data for the markers from early passage (5th) through passages as late as 25 for the different cell lines is presented.

摘要

人类乳腺癌是一组高度异质性的肿瘤，由几种分子亚型组成，这些亚型具有不同的激素、生长因子受体和细胞角蛋白谱[1]。在此，数据展示了属于乳腺癌不同临床亚型的四种不同细胞系的免疫荧光分析。复苏后，这些细胞系在培养中传代，并对雌激素受体（ER）、人表皮生长因子受体2（HER-2）、雄激素受体（AR）和表皮生长因子受体（EGFR）进行免疫表型分析。呈现了不同细胞系从早期传代（第5代）到多达第25代的标志物数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3581/4961495/db1ea892e765/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3581/4961495/db1ea892e765/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3581/4961495/db1ea892e765/gr1.jpg

相似文献

1
Data on alteration of hormone and growth factor receptor profiles over progressive passages of breast cancer cell lines representing different clinical subtypes.关于代表不同临床亚型的乳腺癌细胞系在连续传代过程中激素和生长因子受体谱改变的数据。
Data Brief. 2016 Jul 6;8:944-7. doi: 10.1016/j.dib.2016.07.001. eCollection 2016 Sep.
2
Flow cytometry: a new approach for the molecular profiling of breast cancer.流式细胞术：一种用于乳腺癌分子谱分析的新方法。
Exp Mol Pathol. 2006 Feb;80(1):46-53. doi: 10.1016/j.yexmp.2005.09.007. Epub 2005 Nov 3.
3
Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（HER2）的协同表达在低分化乳腺癌中定义了不同的预后亚型。
Histopathology. 2009 Sep;55(3):346-52. doi: 10.1111/j.1365-2559.2009.03380.x.
4
Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer.乳腺癌细胞系与肿瘤之间分子图谱的全面比较。
BMC Genomics. 2016 Aug 22;17 Suppl 7(Suppl 7):525. doi: 10.1186/s12864-016-2911-z.
5
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.激素和HER-2受体对原发性早期乳腺癌初次手术后的短期预后
Breast Cancer Res Treat. 2009 May;115(2):349-58. doi: 10.1007/s10549-008-0110-6. Epub 2008 Jul 16.
6
Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.基底细胞角蛋白和表皮生长因子受体的表达与三阴性乳腺癌女性的 BRCA1 突变状态无关。
Am J Surg Pathol. 2009 Jul;33(7):1093-7. doi: 10.1097/PAS.0b013e31819c1c93.
7
Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers.通过临床免疫组织化学标志物对乳腺癌细胞系进行分子特征分析。
Oncol Lett. 2017 Jun;13(6):4708-4712. doi: 10.3892/ol.2017.6093. Epub 2017 Apr 25.
8
Steroid hormone receptor gene expression in human breast cancer cells: inverse relationship between oestrogen and glucocorticoid receptor messenger RNA levels.人类乳腺癌细胞中类固醇激素受体基因的表达：雌激素与糖皮质激素受体信使核糖核酸水平之间的负相关关系。
Int J Cancer. 1990 Dec 15;46(6):1081-7. doi: 10.1002/ijc.2910460622.
9
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.激素受体阳性原发性乳腺癌中HER-2/neu与类固醇激素受体之间的定量关联
J Natl Cancer Inst. 2003 Jan 15;95(2):142-53. doi: 10.1093/jnci/95.2.142.
10
Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.类固醇激素受体作为乳腺癌和前列腺癌治疗的靶点——最新进展、耐药机制及新方法
J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):191-200. doi: 10.1016/j.jsbmb.2004.12.002. Epub 2005 Jan 28.

引用本文的文献

1
Cell State Transitions and Phenotypic Heterogeneity in Luminal Breast Cancer Implicating MicroRNAs as Potential Regulators.腔面乳腺癌中的细胞状态转变和表型异质性提示 microRNAs 可能作为潜在的调控因子。
Int J Mol Sci. 2023 Feb 9;24(4):3497. doi: 10.3390/ijms24043497.
2
miR-18a Mediates Immune Evasion in ER-Positive Breast Cancer through Wnt Signaling.miR-18a通过Wnt信号通路介导雌激素受体阳性乳腺癌的免疫逃逸。
Cells. 2022 May 18;11(10):1672. doi: 10.3390/cells11101672.
3
miR-18a activates Wnt pathway in ER-positive breast cancer and is associated with poor prognosis.

本文引用的文献

1
β3 integrin promotes chemoresistance to epirubicin in MDA-MB-231 through repression of the pro-apoptotic protein, BAD.β3整合素通过抑制促凋亡蛋白BAD促进MDA-MB-231对表柔比星的化疗耐药性。
Exp Cell Res. 2016 Aug 1;346(1):137-45. doi: 10.1016/j.yexcr.2016.05.015. Epub 2016 May 26.
2
Molecular portraits of human breast tumours.人类乳腺肿瘤的分子图谱
Nature. 2000 Aug 17;406(6797):747-52. doi: 10.1038/35021093.
miR-18a 在 ER 阳性乳腺癌中激活 Wnt 通路，与不良预后相关。
Cancer Med. 2020 Aug;9(15):5587-5597. doi: 10.1002/cam4.3183. Epub 2020 Jun 16.